Table 1.

Demographic and neuropsychological information for participants.

	Non-Parkinson's disease (n = 41)	Parkinson's disease (n = 60)	P-value
Male:Female	43:7	34:7	0.143
Age (years)	68.29 ± 5.07	67.58 ± 5.51	0.514
Education (years)	16.80 ± 2.25	16.40 ± 2.81	0.444
Sleep Duration	7.44 ± 0.74⁎	6.85 ± 1.25	0.005
Levodopa Equivalency	0.976 ± 6.25⁎⁎	573.65 ± 341.12	0.001
Unified Parkinson Disease Rating Scale-IIIa	3.36 ± 3.82	18.32 ± 9.73	<0.001
Disease duration (years)	–	5.67 ± 5.83	–
Mini-Mental State Examination	29.22 ± 0.96⁎⁎⁎	28.57 ± 1.31	0.008
BDI II	2.98 ± 5.14	8.73 ± 5.57	0.000
Fatigue Severity Scale	3.04 ± 1.32	3.70 ± 1.39	0.019
Leukoariosisb	4194.45 ± 3768.96	3856.14 ± 5022.30	0.716
total intracranial volume	1655418 ± 120427	1688759 ± 158329	0.257
Leukoariosisb/total intracranial volume	0.0025 ± 0.0023	0.0023 ± 0.0029	0.601

^aOn medication.

^bRaw voxel volume.

^⁎Sleep duration = self-report average number of hours of sleep nightly (Non-PD n = 40; PD = 58).

^⁎⁎Levodopa Equivalency = dosage in non- PD peer due to restless leg syndrome.

^⁎⁎⁎PD min = 24; max = 30; non-PD min = 25 max = 30.